Salud Mental

A new challenge for the Mexican health system: hepatitis C in people who inject drugs

##plugins.themes.bootstrap3.article.main##

Carlos Magís-Rodríguez
Rodrigo Marín-Navarrete
Ignacio García-Juárez
DOI: https://doi.org/10.17711/SM.0185-3325.2019.019

Abstract

Injecting-drug use is present in 179 of 206 countries worldwide, with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) prevalence of 17.8% and 52.3%, respectively, among the 15.6 million people who inject drugs (PWIDs) (Degenhardt et al., 2017; Platt et al., 2016). This epidemic produces a high impact on global public health by increasing days lost associated to disability, morbidity, and mortality (Degenhardt et al., 2017).
HTML Pdf ePub

Downloads

Download data is not yet available.
Issue
Vol. 42 No. 4 (2019): Salud mental

References

Comisión Nacional contra las Adicciones (CONADIC). (2017). Observatorio Mexicano de Drogas: Informe sobre consumo de drogas inyectables 2017. Retrieved from: https://www.gob.mx/salud/conadic/acciones-y-programas/observatorio-mexicano-de-drogas-omd

Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., … Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 5(12), e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3

European Monitoring Centre for Drugs and Drug Addiction. (2018). Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). www.emcdda.europa.eu. Retrieved from: http://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en (Access date: September 4, 2019)

Fleiz-Bautista, C., Domínguez-García, M., Villatoro-Velázquez, J. A., Vázquez-Quiroz, F., Zafra-Mora, E., Sánchez-Ramos, R., ... Medina-Mora M. E. (2019). Cuqueando la Chiva: Contextos del consumo de heroína en la frontera norte de México. Ciudad de México, México: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. ISBN: 978-607-98474-0-1

Horyniak, D., Wagner, K. D., Armenta, R. F., Cuevas-Mota, J., Hendrickson, E., & Garfein, R. S. (2017). Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. International Journal of Drug Policy, 47, 9-17. doi: 10.1016/J.DRUGPO.2017.06.006

Magis-Rodríguez, C., García-Sánchez, J. A., & Marín-Navarrete, R. (2018). Harm reduction among people who inject drugs in Mexico. Salud Mental, 41(4), 153-156. doi: 10.17711/SM.0185-3325.2018.023

Nápoles, T. M., Batchelder, A. W., Lin, A., Moran, L., Johnson, M. O., Shumway, M., … Riley, E. D. (2019). HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. Journal of Public Health, fdz045. doi: 10.1093/pubmed/fdz045

Noe, M. H., Grewal, S. K., Shin, D. B., Ogdie, A., Takeshita, J., & Gelfand, J. M. (2017). Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. Journal of the European Academy of Dermatology and Venereology, 31(10), 1674-1680. doi: 10.1111/jdv.14310

Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., … Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 797-808. doi: 10.1016/S1473-3099(15)00485-5

Salmon-Ceron, D., Arends, J. E., Leoni, C., Solas, C., & Peytavin, G. (2019). HIV/HCV Coinfection: Current Challenges. In: Viral Hepatitis: Chronic Hepatitis C (pp. 141-157). Cham: Springer International Publishing. doi: 10.1007/978-3-030-03757-4_7

Stancliff, S., Phillips, B. W., Maghsoudi, N., & Joseph, H. (2015). Harm reduction: Front line public health. Journal of Addictive Diseases, 34(2-3), 206-219. doi: 10.1080/10550887.2015.1059651

Valenzuela-Lara, M., Ponce-Ramos, M., Ruiz-Herrera, K., & López-González, A. (2019). Impact of funding harm reduction programs for people who inject drugs in Mexico. Salud Mental, 42(4), 157-163. doi: 10.17711/SM.0185-3325.2019.021

Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D., & Fraser-Hurt, N. (2015). The cost-effectiveness of harm reduction. International Journal of Drug Policy, 26(Suppl 1), S5-S11. doi: 10.1016/J.DRUGPO.2014.11.007

Xue, W., Liu, K., Qiu, K., Shen, Y., Pan, Z., Hu, P., … Ren, H. (2019). A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation? International Journal of Infectious Diseases, 83, 56-63. doi: 10.1016/J.IJID.2019.03.038

Licencia Creative Commons
Esta obra está bajo una Licencia Creative Commons Atribución-NoComercial 4.0 Internacional.